Sunday Educational Symposium during the ISPOR 3rd Asia-Pacific Conference
SUNDAY, 7 SEPTEMBER 2008 5:00PM-6:00PM
Key Principles for Health Technology Assessment: Turning Principles into Practice
Health technology assessment (HTA) is a dynamic and evolving process, embracing different types of assessments that inform real-world decisions about the value, i.e., benefits, risks, and costs, of new drugs and technologies. In Asian-Pacific countries, the demand for HTA is increasing. Based on the existing experience with HTA worldwide, key principles for HTA are proposed, focusing on:
Governance and structure of the HTA programs
Methods
Processes for conducting HTAs
Use of HTA in decision making.
During this educational symposium, Dr. Sullivan will present the context and key HTA principles. Panelists will also discuss the extent to which the key principles are relevant, comprehensive and pragmatic. The audience is also encouraged to provide input on the proposed principles.
Moderator: Sean D Sullivan PhD, RPh, Professor of Pharmacy and Public Health and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA.
Panelists: Jill M. Sanders PhD, President and CEO, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada;
Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea
Sponsored by Novartis
Sunday Educational Symposium during the ISPOR 3rd Asia-Pacific Conference
SUNDAY, 7 SEPTEMBER 2008
6:15PM-7:15PM
Biologics in Asia-Pacific - New Frontiers in Health Technology Assessment
While offering significant benefits, biologic therapies for rheumatologic disease present new challenges for healthcare systems in Asia-Pacific.
This symposium will offer insights into how cost-effectiveness has been assessed in other parts of the world and will examine the burden of disease in rheumatoid arthritis, including the burden of co-morbidities.
The symposium will consider appropriate methodology for evaluating these new and innovative medicines and ways that constrained health budgets can appropriately address new technologies.
The NICE experience From Rheumatology
Matthew TaylorPhD, Director, York Health Economics Consortium, York University, York, UK
Emerging Data on Ankylosing Spondylitis in Taiwan
Henk Nab MD, PhD, Medical Director, Wyeth Pharmaceuticals Asia Pacific, Selangor Darul Ehsan, Malaysia
Presented in English with Korean Translation
Sponsored by Wyeth
Sunday Educational Symposium during the ISPOR 3rd Asia-Pacific Conference
SUNDAY, 7 SEPTEMBER 2008
7:30PM-8:30PM
Turn Right or Left? – China Health Care Reform at a Crossroad
The health care reform in China is close to a decisive moment. Current health care service, which is considered to be "expensive & difficult to access" by the general public, has aroused more and more debates within the public and become one of the top social issues. In response to this challenge, the Chinese government plans to launch a new round of health care reforms in the coming years.
How does China plan to win this intricate and knotty campaign and achieve the ultimate goal to provide a universal coverage to all 1.3 billion Chinese citizens?
We invite you to join us in a symposium to share the current trend and progress of health care reform in China with three top Chinese scholars. The aim of this symposium is to try to provide a comprehensive understanding of the major challenges of this health care reform in China which is second to none in this world.
Moderator: Zhiqiang Guan MD, MPH, Professor, Beijing Capital Medical University & Senior Public Affairs and Policy Director, Pfizer China, Beijing, P. R. China
CHINA HEALTH CARE REFORM: AN UNPRECEDENTED CHALLENGE Speaker: Jun Liu MD, Deputy Director of Chinese Medical Association, Chief Director of Shanghai Branch,
Shanghai, P. R. China
THE MAIN ISSUES AND TREND OF CHINA HEALTH CARE REFORM Speaker:Hufeng Wang Ph.D, Director of Healthcare Reform and Development Center, China Renmin University,
Beijing, P. R. China
THE CHOICE OF CHINA MEDICINE PRICING POLICY Speaker:JianJun Cao Ph.D, Professor, Institute of Economic Research, National Development & Reform Commission (NDRC), Beijing, P. R. China
